证券代码：300357 证券简称：我武生物 公告编号：2025-034 号 浙江我武生物科技股份有限公司 关于控股股东与实际控制人之间通过大宗交易方式转让公 司股份计划期限届满的公告 股东浙江我武管理咨询有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 截至本公告披露日，本次股份减持计划期限已届满，我武咨询未减持公司股 份。公司控股股东浙江我武管理咨询有限公司与实际控制人之一的胡赓熙先生所 持公司股份未发生变化，具体情况如下： 1 | 股东名称 | 股份性质 | 股数(股) | 占总股本比例(%) | | --- | --- | --- | --- | | 浙江我武管理 咨询有限公司 | 合计持有股份 | 203,454,131 | 38.86% | | | 其中：无限售条件股份 | 203,454,131 | 38.86% | | | 有限售条件股份 | - | - | | 胡赓熙 | 合计持有股份 | 43,698,370 | 8.35% | | | 其中：无限售条件股份 | 10, ...

Group 1: Company Performance and Sales Strategy - The company experienced a recovery in performance starting from the second half of last year, attributed to the appointment of young sales managers who are taking on more responsibilities in various regions [2] - Adjustments to the sales management structure have led to improved efficiency and a more refined management model [2] - Future sales performance will be disclosed in the company's regular reports [2] Group 2: Research and Development Progress - The subsidiary is currently developing allogeneic mesenchymal stem cell therapies, which are in the preclinical research stage [3] - The main challenge in stem cell drug development is ensuring consistent production quality due to variability in the source, culture medium, and methods used [3] - The company has several products in the clinical trial phase, including "Dust Mite Membrane Agent" and diagnostic patches for dermatitis, with the latter entering Phase I clinical trials in August 2025 [3] Group 3: Product Promotion and Market Strategy - The company has launched eight skin prick test products, shifting their positioning from auxiliary desensitization treatments to allergen screening tools [4] - The National Healthcare Security Administration has issued guidelines that allow for the aggregation of charges for different allergen skin tests, which may affect pricing strategies [4] Group 4: Investment in Research and Development - In the first half of 2025, the company invested approximately 61,682,073.51 yuan in R&D, accounting for 12.74% of its revenue [4] - As of June 2025, the company and its subsidiaries employed over 260 R&D personnel, primarily trained in-house [5]

Group 1 - The company's revenue from dust mite drops is gradually recovering, with a revenue of 484 million yuan in the first half of 2025, representing a year-on-year increase of 12.81%, and a net profit of 177 million yuan, up 18.61% year-on-year [1] - The sales revenue of dust mite drops reached 455 million yuan, showing a year-on-year growth of 10.51%, while the sales revenue of Artemisia pollen sublingual drops increased significantly by 71.37% to 21 million yuan [1] - The company has effectively controlled expenses, with a net profit margin of 38.66% in Q2 2025, an increase of 6.4 percentage points year-on-year [1] Group 2 - The company is optimistic about the growth potential of Artemisia pollen drops and allergen prick test products, which are expected to contribute to a second growth curve [2] - The approval of Artemisia pollen drops in January 2021 and the addition of pediatric indications in May 2023 are expected to drive sales growth [2] - The company has launched eight allergen prick test products, which will enhance diagnostic business and increase the penetration rate of allergen testing, supporting the growth of therapeutic desensitization drugs [2] Group 3 - Revenue forecasts for 2025-2027 are projected at 1.054 billion, 1.213 billion, and 1.475 billion yuan, with net profits of 382 million, 454 million, and 581 million yuan respectively, corresponding to PE ratios of 43, 36, and 28 times [3] - The high incidence of allergic rhinitis and asthma, along with increasing recognition of desensitization treatment guidelines, supports the long-term penetration of desensitization therapies [3] - The company initiates coverage with a "buy" rating based on these growth prospects [3]

Core Viewpoint - Iwubio has demonstrated strong growth in revenue and profit in the first half of 2025, driven by its leading position in the allergen desensitization treatment market and the introduction of new products [1][2][3]. Financial Performance - In the first half of 2025, Iwubio achieved revenue of 484 million yuan, a year-on-year increase of 12.81% [1] - The company's net profit attributable to shareholders was 177 million yuan, up 18.61% year-on-year [1] - The revenue from dust mite drops was 455 million yuan, growing by 10.51% [1] - The revenue from the mugwort pollen sublingual drops reached 21.02 million yuan, with a significant increase of 71.37% [1] - The skin prick solution generated revenue of 6.33 million yuan, marking a growth of 104.38% [1] Market Position and Product Development - Iwubio is a core supplier in China's desensitization treatment market, with only its products approved for sublingual allergen desensitization therapy [1][3] - The company has a unique advantage in the allergen product field, which supports its continuous growth [3] - Iwubio has expanded its product matrix with the approval of new skin prick solutions for various allergens [3] Industry Growth Potential - The Chinese allergy drug market is expected to reach 21.6 billion USD by 2030, with a CAGR of 17.1% from 2022 to 2030 [2] - The increasing awareness of allergic diseases among the population and their rising incidence rates are driving market growth [2] Research and Development - Iwubio invested 61.68 million yuan in R&D in the first half of 2025, accounting for 12.74% of its revenue [4] - The company holds 13 valid Chinese invention patents and 7 foreign invention patents, establishing a solid technological barrier [4] - Iwubio is actively involved in clinical research, with numerous studies published in international journals supporting the clinical value of its products [5][6] Future Expansion - Iwubio is exploring new markets, including stem cell therapy and antibiotic resistance, which are projected to have significant growth potential [7][8] - The company aims to enhance its product offerings in the allergy treatment sector while also venturing into emerging medical fields [8]

Core Insights - The social security fund has invested in 396 stocks by the end of Q2, with 37 stocks held for over 20 consecutive quarters, indicating a focus on long-term investments [1][2] Group 1: Investment Trends - The social security fund has consistently held shares in 204 stocks for over four quarters, with 132 stocks held for more than two years [1] - The longest-held stock is Hualu Hengsheng (华鲁恒升), held for 51 quarters since Q4 2012, with a total holding of 133 million shares, accounting for 6.26% of the circulating shares [1][4] - Other long-term holdings include Zhongyuan Media (中原传媒) and WoW Bio (我武生物), held for 44 and 43 quarters respectively [1] Group 2: Stock Performance - Among the 37 stocks held for over five years, the top holdings by quantity are Changshu Bank (常熟银行) with 206 million shares, Sun Paper (太阳纸业) with 151 million shares, and Hualu Hengsheng with 133 million shares [2] - The stocks with the highest holding ratios include Keri International (科锐国际) at 6.30%, Hualu Hengsheng at 6.26%, and Changshu Bank at 6.23% [2] - In terms of changes in holdings, 12 stocks saw an increase in holdings, with significant increases for Three Squirrels (三只松鼠) at 283.29%, Hongfa Co. (宏发股份) at 76.77%, and Hangyang Co. (杭氧股份) at 42.03% [2] Group 3: Industry Distribution - The 37 stocks are concentrated in the basic chemical, electronics, and automotive industries, with 7, 3, and 3 stocks respectively [3] - The basic chemical sector includes Hualu Hengsheng, Yangnong Chemical (扬农化工), and Blue Sky Technology (蓝晓科技) [3] - The electronics sector includes Transsion Holdings (传音控股), Pengding Holdings (鹏鼎控股), and XW Communication (信维通信) [3] Group 4: Financial Performance - Among the 37 stocks, 24 reported year-on-year profit growth, with notable increases from China Jushi (中国巨石) at 75.51%, Jieput (杰普特) at 73.84%, and New Hecheng (新和成) at 63.46% [3] - Conversely, 12 stocks experienced a decline in net profit, with the largest decreases from Zhongqi Co. (中旗股份) at 240.99%, Sanyou Chemical (三友化工) at 77.64%, and Three Squirrels at 52.22% [3]

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]

Core Viewpoint - The strong performance of Iwu Biological's stock is driven by its impressive half-year report and a robust growth strategy in the allergy treatment sector [1][2] Financial Performance - Iwu Biological reported a revenue increase to 484 million yuan, with a net profit of 177 million yuan, and a non-recurring net profit growth rate of 21.97%, indicating double-digit profit growth [1] - The company's gross margin rose to 95.37%, and operating cash flow surged by 96.08% year-on-year, reflecting significant improvement in profitability [1] Product Development - The company is advancing seven research projects, including the upgraded "House Dust Mite Membrane Agent" which entered Phase I clinical trials in March 2025, and the "Dermatitis Diagnostic Patch 02" which received clinical trial approval in May [2] - Iwu Biological holds 20 domestic and international invention patents and invested 61.68 million yuan in R&D, accounting for 12.74% of its revenue, with a research team of over 260 members [2] Market Strategy - The company employs a "scholarly team promotion + commercial distribution" model to enhance awareness of sublingual desensitization therapy among doctors and patients [2] - Iwu Biological has strategically positioned itself in cutting-edge fields such as stem cell therapy and antibiotic resistance, ensuring long-term growth potential [2] Industry Context - The increase in allergy disease prevalence and the rising penetration of desensitization treatments provide a favorable backdrop for Iwu Biological, which is the only company in China with two sublingual desensitization formulations [2]

Core Insights - The Social Security Fund has invested in 313 stocks by the end of Q2, with 20 stocks held for over 20 consecutive quarters [1] - The longest-held stock by the Social Security Fund is Hualu Hengsheng, held for 51 quarters since Q4 2012, with a total holding of 133 million shares, accounting for 6.26% of the circulating shares [1][2] - Among the 20 stocks held for over 5 years, the top holdings by quantity include Changshu Bank, Hualu Hengsheng, and Xiamen Xiangyu, with holdings of 206 million shares, 133 million shares, and 6.39 million shares respectively [2] Holdings Analysis - The Social Security Fund increased its holdings in 8 out of the 20 continuously held stocks by the end of Q2, with significant increases in Hongfa Shares (76.77%), Hangyang Co. (42.03%), and Yilian Network (19.73%) [2] - Conversely, 5 stocks saw a reduction in holdings, with the largest decreases in Zhongqi Shares (-50.14%), Chengyi Pharmaceutical (-8.92%), and Feilihua (-8.70%) [2] Industry Breakdown - The 20 continuously held stocks are concentrated in the basic chemical, pharmaceutical, and electronics industries, with 5, 3, and 2 stocks respectively [3] - The basic chemical sector includes Hualu Hengsheng, Yangnong Chemical, and Lanxiao Technology, while the pharmaceutical sector includes Iwu Biological, Chengyi Pharmaceutical, and New Industry [3] Performance Overview - Among the continuously held stocks, 13 reported year-on-year profit growth in the first half of the year, with notable increases from Jieput (73.84%), Pengding Holdings (57.22%), and Chengyi Pharmaceutical (47.03%) [3] - 7 stocks experienced a decline in net profit, with Zhongqi Shares (-240.99%), Hualu Hengsheng (-29.47%), and Xinwei Communication (-20.18%) showing the largest decreases [3]

Core Viewpoint - Iwubio reported strong financial performance for the first half of 2025, with significant increases in revenue and net profit compared to the previous year, indicating robust growth in the allergy treatment sector [1][3]. Financial Performance - Total revenue for the first half of 2025 reached 484 million yuan, a year-on-year increase of 12.81% [1] - Net profit attributable to shareholders was 177 million yuan, up 18.61% year-on-year [1] - In Q2 2025, total revenue was 256 million yuan, reflecting a 20.07% increase year-on-year, while net profit for the quarter was 103 million yuan, up 42.55% [1] - Gross margin improved to 95.1%, an increase of 0.16% year-on-year, and net margin rose to 35.2%, up 5.93% [1] - Total operating expenses were 202 million yuan, accounting for 41.67% of revenue, a decrease of 1.15% year-on-year [1] Cash Flow and Financial Health - Operating cash flow per share increased by 96.08% to 0.38 yuan, driven by higher cash receipts from sales [3] - The company reported a significant decrease in interest-bearing debt, down 80.21% to 10.13 million yuan, indicating improved financial stability [1][3] - The net increase in cash and cash equivalents was 102.17%, influenced by changes in operating, investing, and financing activities [3] Business Model and Market Position - Iwubio focuses on the treatment of allergic diseases, leveraging its R&D capabilities to develop desensitization products [5] - The company’s business model is primarily driven by marketing efforts, which require careful analysis of the underlying drivers [3] - The company has a historical median ROIC of 19.19%, indicating strong investment returns over the past decade [3] Future Outlook - Analysts project that Iwubio's revenue for 2025 will reach 352 million yuan, with an average earnings per share estimate of 0.67 yuan [4]

Core Viewpoint - Iwubio (300357.SZ) reported a strong mid-year performance with double-digit growth in both revenue and profit, driven by its core products and a robust innovation system [1][2][3] Financial Performance - Revenue increased to 484 million yuan, a year-on-year growth of 12.81% - Net profit attributable to shareholders reached 177 million yuan, with a year-on-year increase of 18.61% - Deducting non-recurring gains, net profit grew by 21.97% to 173 million yuan - Gross margin improved to 95.37%, and operating cash flow surged by 96.08% to 200 million yuan [1][3][4] Product Performance - The main product, "Dust Mite Drops," generated sales of 455 million yuan, up 10.51% year-on-year - "Artemisia Pollen Drops" sales reached 21.02 million yuan, a growth of 71.37% - "Skin Prick Test Kit" sales amounted to 6.33 million yuan, increasing by 104.38% [2][3][4] R&D and Innovation - R&D investment accounted for 12.74% of revenue, totaling 61.68 million yuan - The company has 7 products in the pipeline, including "House Dust Mite Membrane" which is in Phase I clinical trials - Iwubio holds 13 valid Chinese invention patents and 7 foreign invention patents [4][5][6] Market Strategy - The company employs an efficient sales model combining academic promotion and commercial distribution - Iwubio is expanding its strategic focus to include stem cell therapy and natural medicines, laying a foundation for long-term growth [6]